Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 2/20 | 0.45 |
| ▸ | INSR | P06213 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.43 |
| ▸ | CDK2 | P24941 | 5/20 | 0.43 |
| ▸ | CCNK | O75909 | 4/20 | 0.43 |
| ▸ | CCND3 | P30281 | 4/20 | 0.43 |
| ▸ | CDK9 | P50750 | 4/20 | 0.43 |
| ▸ | CDK6 | Q00534 | 4/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.42 |
| ▸ | AXL | P30530 | 7/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2060765 | 0.77 | CCNA2 (0.52) | ADRA1ACCNA2CDK2CCNKCCND3 | |
| SCHEMBL30394901 | 0.76 | CCNA2 (0.63) | ALKCCNA2CDK2CCNKCCND3 | |
| SCHEMBL26161918 | 0.76 | CCNA2 (0.63) | ALKCCNA2CDK2CCNKCCND3 | |
| SCHEMBL886547 | 0.75 | AXL (0.56) | ALKINSRPTK2CCNA2CDK2 | |
| SCHEMBL24073481 | 0.75 | YTHDC1 (0.42) | ALKINSRPTK2CCNA2CDK2 | |
| SCHEMBL2062564 | 0.74 | IGF1R (0.54) | ALKCCNA2CDK2CCNKCCND3 | |
| SCHEMBL2062459 | 0.73 | AXL (0.58) | ALKCCNA2CDK2CCNKCCND3 | |
| SCHEMBL2061644 | 0.73 | LRRK2 (0.46) | ADRA1ACCNA2CDK2CCNKCCND3 | |
| SCHEMBL17545206 | 0.73 | CCNA2 (0.43) | ALKADRA1AADRA1BCCNA2CDK2 | |
| SCHEMBL2062194 | 0.73 | CCNA2 (0.40) | ALKCCNA2CDK2CCNKCCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2222647-B1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2684874-A1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | Cephalon, Inc. (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8552186-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors | CEPHALON, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | CEPHALON, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8148391-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-2222647-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | Cephalon, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | ALK, MET, RET | ALK 1/4885INSR 241/4885PTK2 491/4885 |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | ALK, MET, RET | ALK 1/4885INSR 241/4885PTK2 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.